BioSpace News Archive

Adaptive Biotechnologies Corporation (Nasdaq: ADPT), together with its collaborators, will present data from more than 30 abstracts showcasing the benefit of Adaptive’s next-generation sequencing (NGS)-based clonoSEQ ® Assay in measuring minimal residual disease (MRD) in blood cancer patients at the 64th Annual Meeting of the American Society of Hematology (ASH) taking place December 10-13, 2022.

Biognosys, a leader in next-generation proteomics solutions for life science research and drug development, will launch Spectronaut 17 at the HUPO 2022 World Congress in Cancun, Mexico.

BrainTale has presented the “Evaluation of a clinically validated digital platform to provide Diffusion MRI biomarkers in Alzheimer’s disease” during the 15th edition of the Clinical Trials on Alzheimer’s Disease conference (CTAD 2022) held in San Francisco and online from November 29 to December 2, 2022.

Leading pharmacy benefit manager (PBM) Prime Therapeutics LLC (Prime) today finalized the previously announced acquisition of Magellan Rx Management, (Magellan Rx), the pharmacy division of Magellan Health, from Centene Corporation.

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) today announced new real-world data from the BECOME (BEhavior, COgnition, and More with Epidiolex ®) Caregiver Survey that showed a substantial proportion of caregivers of adult and pediatric patients with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS) prescribed Epidiolex.

CNS Pharmaceuticals, Inc. today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals, will participate in the Virtual Investor “Ask the CEO” Event on Tuesday, December 6, 2022 at 11:00 AM ET.

Aviceda Therapeutics has completed a key IND-enabling milestone for its HALOS™ technology platform by demonstrating a very favorable safety profile at numerous tolerated doses of its lead ophthalmic drug candidate, AVD-104, in non-human primates and rabbits.

Neuronetics, Inc. is named a 2022 bronze winner by the Merit Awards for Healthcare in the HealthTech Patient Care category for its NeuroStar Advanced Therapy.

ENDRA Life Sciences Inc. announced today that it will be effecting a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20.

Corvus Pharmaceuticals, Inc. announced that it will host an investor conference call to provide an update on CPI-818 data that will be presented at the 64th American Society of Hematology Annual Meeting and Exposition, along with an update on the Company’s development programs.